Toxicity after abiraterone acetate treatment of a patient with advanced prostate cancer — a case study

Abstract

The description presents a 69-year-old man with prostate cancer, who despite the lack of primary radical treatment of local disease benefited from hormonotherapy, and after resistance to castration also from chemotherapy. Despite significantly advanced disease, rapidly increasing PSA antigen level, the patient remained asymptomatic for 8 years. The administration of treatment with abiraterone acetate allowed to obtain biochemical response, though it revealed meaningful cardiologic toxicity preventing from further treatment.